Recombinant Human Cadherin-9 Fc Chimera Protein, CF

WhenRecombinant Human Cadherin 9 Fc Chimera is immobilized at 1 μg/mL, 100 μL/well,Recombinant Human Cadherin‑6/KCAD Fc Chimera (Catalog # 2715-CA) binds with an ED50 of 0.6-3.6μg/mL.

2 μg/lane of Recombinant Human Cadherin-9 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 92‑106 kDa and 180‑210 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Cadherin-9 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Cadherin-9 Fc Chimera is immobilized at 1 μg/mL, 100 μL/well, Recombinant Human Cadherin‑6/KCAD Fc Chimera (Catalog # 2715-CA) binds with an ED₅₀ of 0.6-3.6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Cadherin-9 protein
  

  Human Cadherin-9 (Gly54-Ala615) Accession # Q9ULB4	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q9ULB4
• N-terminal Sequence: Gly54
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 89.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 92-106 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Cadherin-9 Fc Chimera Protein, CF

• cadherin 9, type 2 (T1-cadherin)
• Cadherin9
• Cadherin-9
• CDH9
• T1-Cadherin

Background

Cadherin-9 (CDH9) is a member of the larger Cadherin superfamily of cell surface glycoproteins originally identified as proteins mediating cell-cell adhesion (1). In humans, there are more than 100 cadherin members divided into distinct families and numerous sub-families (1-3). Cadherins share a general structural architecture with an extracellular domain (ECD) containing 2 or more extracellular Ca2⁺ binding cadherin repeat (EC) domains, a single-pass transmembrane section, and a short cytoplasmic tail (1-3). Cadherins function by forming homophilic binding interactions through these EC domains to generate both trans and cis dimers (1-3). Human CDH9 is categorized as a classical cadherin, containing 5 EC domains, and the ECD shares 94% amino acid sequence identity with the ECD of both mouse and rat CDH9, respectively. Cadherins are found in diverse cell types and have been implicated as essential for the morphogenesis and homeostasis of multiple tissues and organs (1-3). Human CDH9 functions primarily in the central nervous system and is expressed in DG and CA3 neurons. Loss of CDH9 expression leads to defects in synapse formation and differentiation of specific neural circuits. (4). Additionally, disruption to CDH9 and CDH10 genes has been linked to autism spectrum disorders (5, 6). CDH9 expression has been identified in human kidney, and it has been used as a cell surface marker for fibroblasts (7). Recently, CDH9 has been reported as a potential suppressor of cancer metastasis (8).

1. Gumbiner, B.M. (2005) Nat. Rev. Mol. Cell Biol. 6:622.
2. Hirano S and Takeichi M. (2012) Physiol Rev. Apr; 92(2):597.
3. Nollet et al. (2000) J Mol Biol. Jun. 9; 299(3):551.
4. Williams ME et al. (2011) Neuron. Aug. 25; 71(4):640.
5. Wang K. et al. (2009) Nature 459, 528.
6. Inoue YU and, Inoue T. (2016) Sci Rep. 6:31227.
7. Thedieck, C. et al. (2007) PLoS One. 2(8):e657.
8. Yan G. et al. (2017) Scientific Reports volume 7, 10023.

Publications for Cadherin-9 (9984-CA)(1)

Publication using 9984-CA

• Suzuki, H;Nagase, S;Saito, C;Takatsuka, A;Nagata, M;Honda, K;Kaneda, Y;Nishiya, Y;Honda, T;Ishizaka, T;Nakamura, K;Nakada, T;Abe, Y;Agatsuma, T; Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models Molecular cancer therapeutics 2024-01-11 [PMID: 38205802] (ELISA Capture, N/A)

Bioinformatics

• Uniprot:
  • Q9ULB4()